Production of the HIV-suppressive chemokines CCL3/MIP-1α and CCL22/MDC is associated with more effective antiretroviral therapy in HIV-infected children

Pediatric Infectious Disease Journal

Volumn 26, Issue 10, 2007, Pages 935-944

  Lambert, John S ^a   Machado, Elizabeth S ^b   Watson, Douglas C ^c   Sill, Anne M ^d   Lim, Jean K ^d   Charurat, Manhattan ^d   Cunha, Silvia M ^b   Afonso, Adriana O ^b   Oliviera, Ricardo H ^b   Tanuri, Amilcar ^b   DeVico, Anthony L ^d  

^a MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c UNIVERSITY OF MARYLAND   (United States)

^d INSTITUTE OF HUMAN VIROLOGY   (United States)

Author keywords

Antiretrovirals; Chemokines; Children; HIV

Indexed keywords

DIDANOSINE; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; MACROPHAGE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; NELFINAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ARTICLE; BRAZIL; CD4+ T LYMPHOCYTE; CELL CULTURE; CHILDHOOD DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFICACY; FEMALE; GENE MUTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRESCHOOL CHILD; PRIORITY JOURNAL; VIRUS LOAD;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BRAZIL; CD4 LYMPHOCYTE COUNT; CELLS, CULTURED; CHEMOKINE CCL22; CHEMOKINE CCL3; CHILD; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; TREATMENT OUTCOME; VIRAL LOAD;

EID: 34848867871     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/INF.0b013e31812714db     Document Type: Article

References (40)

1. + lymphocytes can control HIV infection in vitro by suppressing virus replication. Science. 1986;234:1563-1566.
2. Fauci AS. Host factors and the pathogenesis of HIV-induced disease. Nature. 1996;384:529-534.
3. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol. 1999;17:657-700.
4. + T cells. Science. 1995;270:1811-1815.
5. Alkhatib G, Locati M, Kennedy PE, Murphy PM, Berger EA. HIV-1 coreceptor activity of CCR5 and its inhibition by chemokines: independence from G protein signaling and importance of coreceptor down-modulation. Virology. 1997;234:340-348.
6. Pierson TC, Doms RW. HIV-1 entry and its inhibition. Curr Top Microbiol Immunol. 2003;281:1-27.
7. Zhu T, Mo H, Wang N, et al. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science. 1993;261:1179-1181.
8. van't Wout AB, Kootstra NA, Mulder-Kampinga GA, et al. Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission. J Clin Invest. 1994;94:2060-2067.
9. DeVico AL, Gallo RC. Control of HIV-1 infection by soluble factors of the immune response. Nat Rev Microbiol. 2004;2:401- 413.
10. Agrawal L, Vanhorn-Ali Z, Alkhatib G. Multiple determinants are involved in HIV coreceptor use as demonstrated by CCR4/CCL22 interaction in peripheral blood mononuclear cells (PBMCs). J Leukoc Biol. 2002;72:1063-1074.
11. Cota M, Mengozzi M, Vicenzi E, et al. Selective inhibition of HIV replication in primary macrophages but not T lymphocytes by macrophage-derived chemokine. Proc Natl Acad Sci U S A. 2000;97:9162-9167.
12. Moriuchi H, Moriuchi M. Dichotomous effects of macrophage-derived chemokine on HIV infection. Aids. 1999;13:994-996.
13. Pal R, Garzino-Demo A, Markham PD, et al. Inhibition of HIV-1 infection by the beta-chemokine MDC. Science. 1997;278:695-698.
14. Struyf S, Proost P, Sozzani S, et al. Enhanced anti-HIV-1 activity and altered chemotactic potency of NH2-terminally processed macrophage-derived chemokine (MDC) imply an additional MDC receptor. J Immunol. 1998;161:2672-2675.
15. Ullum H, Cozzi Lepri A, Victor J, et al. Production of beta-chemokines in human immunodeficiency virus (HIV) infection: evidence that high levels of macrophage inflammatory protein-1beta are associated with a decreased risk of HIV disease progression. J Infect Dis. 1998;177:331-336.
16. Garzino-Demo A, Moss RB, Margolick JB, et al. Spontaneous and antigen-induced production of HIV-inhibitory beta-chemokines are associated with AIDS-free status. Proc Natl Acad Sci U S A. 1999;96:11986-11991.
17. Zagury D, Lachgar A, Chams V, et al. C-C chemokines, pivotal in protection against HIV type 1 infection. Proc Natl Acad Sci U S A. 1998;95:3857-3861.
18. + lymphocytes from exposed-uninfected individuals: association with low expression of CCR5 and high production of beta-chemokines. Virology. 1998;244:66-73.
19. + T cells are associated with asymptomatic HIV-1 infection. Proc Natl Acad Sci U S A. 2000;97:13812-13817.
20. Skurnick JH, Palumbo P, DeVico A, et al. Correlates of nontransmission in US women at high risk of human immunodeficiency virus type 1 infection through sexual exposure. J Infect Dis. 2002;185:428- 438.
21. Gonzalez E, Kulkarni H, Bolivar H, et al. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science. 2005;307:1434-1440.
22. An P, Nelson GW, Wang L, et al. Modulating influence on HIV/AIDS by interacting RANTES gene variants. Proc Natl Acad Sci U S A. 2002;99:10002-10007.
23. Liu H, Chao D, Nakayama EE, et al. Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression. Proc Natl Acad Sci U S A. 1999;96:4581- 4585.
24. McDermott DH, Beecroft MJ, Kleeberger CA, et al. Chemokine RANTES promoter polymorphism affects risk of both HIV infection and disease progression in the Multicenter AIDS Cohort Study. Aids. 2000;14:2671-2678.
25. Brichacek B, Bukrinsky M. Highly active antiretroviral therapy and beta-chemokines. Clin Exp Immunol. 2002;130:169-171.
26. Fransen S, Copeland KF, Smieja M, Smaill F, Rosenthal KL. RANTES production by T cells and CD8-mediated inhibition of human immunodeficiency virus gene expression before initiation of potent antiretroviral therapy predict sustained suppression of viral replication. J Infect Dis. 2000;181:505-512.
27. Carter LM, Peters BS, Ellis BA, Wolstencroft RA. Highly active antiretroviral therapy normalizes the potential for MIP-1alpha production in HIV infection. J Infect. 2000;41:252-255.
28. Kumar D, Parato K, Kumar A, Sun E, Cameron DW, Angel JB. Sustained suppression of plasma HIV RNA is associated with an increase in the production of mitogen-induced MIP-1alpha and MIP-1beta. AIDS Res Hum Retroviruses. 1999;15:1073-1077.
29. Machado ES, Lambert JS, Watson DC, et al. Genotypic resistance and HIV-1 subtype in Brazilian children on dual and triple combination therapy. J Clin Virol. 2004;30:24-31.
30. Machado ES, Lambert JS, Afonso AO, et al. Overview of genotypic and clinical profiles of human immunodeficiency virus type 1-infected children in Rio de Janeiro, Brazil. An Acad Bras Cienc. 2004;76:727-741.
31. Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. U.S. Department of Health and Human Services AIDSinfo website; 2005. Available at: http://www.aidsinfo-.nih.gov/guidelines/.
32. Centers for Disease Control and Prevention. 1994 revised classification system for human immunodeficiency infection in children less than 13 years of age. MMWR. 1994;43:1-10.
33. Galli G, Chantry D, Annunziato F, et al. Macrophage-derived chemokine production by activated human T cells in vitro and in vivo: preferential association with the production of type 2 cytokines. Eur J Immunol. 2000;30:204-210.
34. Mantovani A, Gray PA, Van Damme J, Sozzani S. Macrophage-derived chemokine (MDC). J Leukoc Biol. 2000;68:400-404.
35. Iellem A, Colantonio L, Bhakta S, et al. Inhibition by IL-12 and IFN-alpha of I-309 and macrophage-derived chemokine production upon TCR triggering of human Th1 cells. Eur J Immunol. 2000;30:1030-1039.
36. Abdelwahab SF, Cocchi F, Bagley KC, et al. HIV-1-suppressive factors are secreted by CD4 T cells during primary immune responses. Proc Natl Acad Sci U S A. 2003;100:15006-15010.
37. Than S, Tumaliuan JA, Tamma S, Morales M, Bakshi S, Pahwa S. Chemokine pattern in relation to disease state in human immunodeficiency virus-infected children. AIDS Res Hum Retroviruses. 1999;15:1279-1285.
38. Resino S, Bellon JM, Gurbindo D, Munoz-Fernandez MA. Disruption in cytokine and chemokine production by T-cells in vertically HIV-1-infected children. Acta Paediatr. 2001;90:989-997.
39. Wasik TJ, Bratosiewicz J, Wierzbicki A, et al. Protective role of beta-chemokines associated with HIV-specific Th responses against perinatal HIV transmission. J Immunol. 1999;162:4355-4364.
40. + T cell surface CC chemokine receptor 5 density in human immunodeficiency virus type 1 vertical infection. J Infect Dis. 2002;185:1055-1061.